Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 05 May 2015
At a glance
- Drugs Acetylcysteine (Primary) ; Disufenton (Primary) ; Disufenton/acetylcysteine (Primary)
- Indications Hearing loss; Noise-induced hearing loss; Sensorineural hearing loss
- Focus Adverse reactions
- Sponsors Otologic Pharmaceutics
- 30 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Dec 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 30 Oct 2014 New trial record